



**Editor-in-Chief**  
Pedro T Ramirez (USA)

**Associate Editors**  
Antonio Gonzalez (Spain)  
Anna Fagotti (Italy)  
Michael Frumovitz (USA)  
Rene Pareja (Colombia)  
Anuja Jhingran (USA)

**Video Editor**  
Luis Chiva (Spain)

**Social Media Editor**  
Ane Gerda Zahl Eriksson (Norway)

**Managing Editor**  
Lindsey Struckmeyer (USA)

**Editorial Office**  
*International Journal of Gynecological Cancer*, BMJ Journals  
Two Hudson Square, 3rd Floor,  
Hoboken, NJ 07030 USA  
E: [ijgc@jgeditorial.com](mailto:ijgc@jgeditorial.com)

**Production Editor**  
Hannah Martin  
E: [production.ijgc@bmj.com](mailto:production.ijgc@bmj.com)

**Customer support**  
For general queries and support with  
existing and new subscriptions:  
W: [support.bmj.com](mailto:support.bmj.com)  
T: +44 (0)20 7111 1105  
E: [support@bmj.com](mailto:support@bmj.com)

Self-archiving and permissions  
W: [bmj.com/company/productservices/rights-and-licensing/](http://bmj.com/company/productservices/rights-and-licensing/)  
E: [bmj.permissions@bmj.com](mailto:bmj.permissions@bmj.com)

**Disclaimer:** The Editor of *International Journal of Gynecological Cancer* has been granted editorial freedom and *International Journal of Gynecological Cancer* is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. *International Journal of Gynecological Cancer* is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by *International Journal of Gynecological Cancer* does not imply endorsement. Neither *International Gynecologic Cancer Society* and *European Society of Gynaecological Oncology* nor BMJ Publishing Group Limited shall have any liability for any loss, injury or damage howsoever arising from *International Journal of Gynecological Cancer* (except for liability which cannot be legally excluded).

**Copyright:** © 2021 IGCS and ESGO. All rights reserved; no part of this publication may be reproduced in any form without permission.

The *International Journal of Gynecological Cancer (IJGC)* is published by BMJ Publishing Group Ltd and typeset by Exeter Premedia Services Private Limited, Chennai, India.

## Lead Article

- 801** Evaluating meaningful levels of financial toxicity in gynecologic cancers  
*K McK Esselen, A Gompers, M R Hacker, S Boubberhan, M Shea, S S Summerlin, L R Rucker, W K Huh, M Pisu, M I Liang*

## Editorial

- 807** Financial toxicity is common among gynecologic cancer patients  
*R F Harrison, L A Meyer*

## Preinvasive Disease

- 808** A cross-sectional study exploring triage of human papillomavirus (HPV)-positive women by visual assessment, manual and computer-interpreted cytology, and HPV-16/18–45 genotyping in Cameroon  
*P Vassilakos, A Wisniak, R Catarino, E Tincho Fogueim, C Balli, E Saiji, J-C Tille, B Kenfack, P Petignat*

## Vulvar Cancer

- 817** Technique for inguino-femoral lymph node dissection in vulvar cancer: an international survey  
*S E F Jones, P T Ramirez, G P Bhandoria, H-C Hsu, N Nair, F Noll, C N Hurt, R Howells, K Lim, A Sharma*

## Cervical Cancer

- 824** Combination of weekly paclitaxel-carboplatin plus standard bevacizumab as neoadjuvant treatment in stage IB–IIB cervical cancer  
*C Maene, R R Salih, E Van Nieuwenhuysen, S N Han, N Concin, I Vergote*
- 829** Role of adjuvant radiation therapy after radical hysterectomy in patients with stage IB cervical carcinoma and intermediate risk factors  
*D Nasioudis, N A Latif, R L Giuntoli II, A F Haggerty, L Cory, S H Kim, M A Morgan, E M Ko*

- 835** Impact of three-dimensional chemoradiation on pelvic bone mineral density, low back pain, and disability in cervical cancer: a prospective study  
*D Kumar, R Miriyala, B Rai, P Bansal, A S Oinam, T Singh, S Ghoshal*

## Uterine Cancer

- 840** The impact of sentinel lymph node sampling versus traditional lymphadenectomy on the survival of patients with stage IIIC endometrial cancer  
*D Nasioudis, M Byrne, E M Ko, R L Giuntoli II, A F Haggerty, L Cory, S H Kim, M A Morgan, N A Latif*
- 846** Lynch syndrome associated endometrial carcinomas in Western Australia: an analysis of universal screening by mismatch repair protein immunohistochemistry  
*S Gupta, C B Nichols, J Phillips, S O'Sullivan, C Ayres, G R Mohan, Y Leung, C J R Stewart, A Tan, L Schofield, S G Salfinger, C Kiraly-Borri, N Pachter, P A Cohen*
- 852** Chemotherapy response score as a prognostic tool in patients with advanced stage endometrial carcinoma treated with neoadjuvant chemotherapy  
*I Jani, R R Lastra, K S Brito, C Liao, I Lazo, N K Lee, S D Yamada, K C Kurnit*

- 859** Adjuvant brachytherapy for FIGO stage I serous or clear cell endometrial cancer  
*E B Jeans, W G Breen, T C Mullikin, B A Looker, A Mariani, G L Keeney, M G Haddock, I A Petersen*

- 868** Detection of microRNA in urine to identify patients with endometrial cancer: a feasibility study  
*H Donkers, M Hirschfeld, D Weiß, T Erbes, M Jäger, J Pijnenborg, R Bekkers, K Galaal*

## Ovarian Cancer

- 875** Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study

*G Daniele, F Raspagliesi, G Scambia, C Pisano, N Colombo, S Frezzini, G Tognon, G Artioli, A Gadducci, R Lauria, A Ferrero, S Ciniari, A De Censi, E Breda, P Scollo, U De Giorgi, A A Lissoni, D Katsaros, D Lorusso, V Salutati, S C Cecere, E Zaccarelli, M Nardin, G Bogani, M Distefano, S Greggi, M C Piccirillo, R Fossati, G Giannone, L Arenare, C Gallo, F Perrone, S Pignata*

- 883** Feasibility of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer during COVID-19 pandemic



*A Ayhan, S Yilmaz Baran, D Vatanserver, G Dogan Durdag, H Akilli, H Celik, C Taskiran*

- 888** Practice patterns in post-treatment surveillance in patients with primary epithelial ovarian cancer

*J DeMari, M H Vetter, S Chandra, J L Hays, R Salani*

- 893** Role of inhibin B in detecting recurrence of granulosa cell tumors of the ovary in postmenopausal patients

*R Portuesi, A Loppini, R Mancari, S Filippi, N Colombo*

## Pregnancy and Fertility

- 899** Management of ovarian masses in pregnancy: patient selection for interventional treatment

*A C Testa, F Masilini, L Quagliozzi, F Moro, G Bolomini, M T Mirandola, M C Moruzzi, G Scambia, A Fagotti*

## Reviews

- 907** p53abn Endometrial Cancer: understanding the most aggressive endometrial cancers in the era of molecular classification

*A Jamieson, E F Thompson, J Huvila, C B Gilks, J N McAlpine*

- 914** Gynecologic cancer surveillance in the era of SARS-CoV-2 (COVID-19)

*G Mancebo, J-M Solé-Sedeño, I Membrive, A Taus, M Castells, L Serrano, R Carreras, E Miralpeix*

## Clinical trial

- 920** TRAINING-Ovary 01 (connected pRehabiliAtIoN pelvic caNcer surGery): multicenter randomized study comparing neoadjuvant chemotherapy for patients managed for ovarian cancer with or without a connected pre-habilitation program

*E Lambaudie, C Bannier/Braticevic, C Villaron/Goetgheluck, C Zemmour, J-M Boher, P Ben Soussan, J Pakradouni, C Brun, L Lopez Almeida, P Marino*

## Case study

- 925** Management of Wolffian adnexal tumors

*S R Kim, F Heredia, S Pakbaz, U Metser, S Laframboise*

## Corners of the world

- 929** Project ECHO in Belarus: outcomes of 3-year experience

*O P Matylevich, A B Shushkevich, P A Perevoschikov, S A Mavrichev, K M Schmeler*

## Video articles

- 932** Assessment of anastomotic perfusion using indocyanine green fluorescence angiography following bowel resection for gynecologic malignancies: an instructional surgical video

*E Spenard, J M V Nguyen, T May*

- 934** Three-dimensional virtual histology of benign and malignant endometrial stromal neoplasms: a new perspective on why morphology matters



*F KF Kommos, J Albers, C Schwab, W L Wagner, G Tromba, C Dullin*

- 936** Pelvic anatomy for gynecologic oncologists: autonomic bladder plexus

*B Díaz-Feijoo, M Rius, M Gracia, N Agusti, F Carmona*

## Educational video lecture

- 938** Ultrasound, macroscopic and histological features of endometrioid and clear cell ovarian cancer

*G Bolomini, V Bertoldo, G F Zannoni, F Pozzati*

---

**Pathology archives**

- 940** Immature teratoma with associated gliomatosis peritonei: image and brief review of literature  
*C Schwartz, M Osorio, N Banet*

---

**Images**

- 942** Purple bag syndrome: a visual clue for infection  
*V Wang, R Harrison*

---

**Commentaries**

- 943** Immediate lymphatic reconstruction: the time is right to prevent lymphedema following lymphadenectomy for vulvar cancer  
*C Ince, C Temple-Oberle, M M Leitao Jr., M Coriddi, G Nelson*

- 944** Incorporating molecular profiling into endometrial cancer management requires prospective studies  
*F Amant, W G McCluggage, H M J Werner, J C Kasius, C Krakstad, J Pijnenborg*

---

**Letters**

- 946** Are we confident treating pT1a G1 lymphovascular space invasion-negative patients (with myometrial invasion) with chemoradiotherapy on the basis of p53abn?  
*A Merlotti, E Russi, V De Sanctis*
- 947** Response to: Are we confident treating pT1a G1 lymphovascular space invasion-negative patients (with myometrial invasion) with chemoradiotherapy on the basis of p53abn?  
*N Concin, X Matias-Guiu, CL Creutzberg, on behalf of the ESGO-ESTRO-ESP Endometrial Carcinoma Guideline Working Group*